Investment Rating - The report gives an "Overweight" rating for the logistics industry, indicating a positive outlook for the sector compared to the overall market performance [2]. Core Insights - Alibaba's strategic upgrade of its Taobao Flash Purchase is expected to drive significant demand in the instant delivery sector, with a focus on becoming the absolute leader in the market. This shift is anticipated to foster healthy growth across all categories in instant delivery, especially under the current anti-monopoly regulations [2]. - The competition in instant delivery is likely to trigger a new "arms race" among brands and merchants, which will positively impact the logistics side, creating a virtuous cycle of growth [2]. - Third-party logistics service providers, such as SF Express, are expected to benefit from the competitive landscape, with significant growth in delivery volumes during peak periods like "Double Eleven" [2]. Summary by Sections Industry Overview - The instant delivery sector is evolving, with a shift from food and beverage categories to higher-ticket items, providing more growth opportunities for logistics [2]. - High-frequency subsidies have successfully cultivated consumer habits, which will directly increase the volume of instant delivery orders [2]. Company Analysis - SF Express has shown remarkable performance, with daily delivery volumes increasing by over 50% year-on-year during peak shopping events. The growth in non-food categories, such as beauty and jewelry, has also been notable [2][3]. - The report highlights the significant value of SF Express as a neutral third-party platform, benefiting from increased order volumes from various e-commerce platforms [2]. Investment Recommendations - The report recommends focusing on SF Express due to its consistent profitability and significant third-party value, while also keeping an eye on Flash Delivery [2].

Investment Rating - The industry investment rating is positive, indicating an overweight outlook for the AIDC sector, suggesting it will outperform the overall market [8]. Core Insights - The AIDC industry is expected to experience significant breakthroughs in computing power, models, and applications in 2026, with domestic computing power transitioning from usable to highly effective [2]. - The demand from cloud vendors remains strong, with a notable increase in IDC orders expected to be fulfilled by mid-2026, indicating a robust growth trajectory for cloud computing infrastructure [2]. - The supply side faces challenges due to the scarcity of effective supply, as the government emphasizes orderly guidance and efficient construction of intelligent computing centers [2]. Summary by Sections Demand Side - Cloud vendors are expected to have high demand for IDC, with orders from Q1 2025 anticipated to be deployed by Q2-Q3 2026, necessitating significant capital investment [2]. - The new round of IDC bidding has commenced, with an accelerated delivery schedule expected [2]. Supply Side - The government is focusing on optimizing the layout of intelligent computing resources, which will create a balanced supply-demand situation in the long term [2]. - There is a noted expectation for supply of supporting equipment, such as UPS and HVDC systems, to meet the needs of AIDC construction [2]. Key Companies - Key players in the industry include leading IDC companies like Runze Technology and Dongyangguang, as well as emerging companies like Aofei Data and Guanghuan New Network [2]. - Companies providing essential supply and cooling solutions, such as Kehua Data and Zhongheng Electric, are also highlighted as important players [2].

行 业 及 产 业 商贸零售/ 互联网电商 行 业 研 究 / 行 业 点 评 券 研 究 报 告 《阿里巴巴-W（09988）深度：阿里云全 栈 AI+TOC 入口，AI 重估继续（阿里巴巴 深度之四暨 GenAI 系列报告之 67）》 2025/12/24 《全球大模型能力再升级，阿里持续加码 全栈 AI 能力——商贸零售行业周报 （11.24-11.28）》 2025/12/01 本期投资提示： 证 请务必仔细阅读正文之后的各项信息披露与声明 证券分析师 赵令伊 A0230518100003 zhaoly2@swsresearch.com 联系人 张蕴达 A0230125030003 zhangyd@swsresearch.com 2026 年 01 月 14 日 GEO 重塑营销范式，阿里巴巴或为 超级入口 看好 ——阿里系列研究之 AI 专题 本研究报告仅通过邮件提供给 中庚基金 使用。1 相关研究 《阿里巴巴（BABA）点评：阿里云继续加 速增长，投入即时零售深化生态协同》 2026/01/12 ⚫ AI 搜索崛起引发信息获取入口变革，GEO 打造企业营销新范式。近期传统搜索引擎使 用规模与渗透率 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the market [6]. Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6]. - The acquisition of Nanda Pharmaceutical is expected to enhance the company's integrated strategy of "raw materials + formulations," increasing its direct stake to 73.358% [6]. - The company has a robust pipeline of human-derived protein products, including new drugs AD010, AD108, and ADB116, with AD108 and ADB116 receiving clinical approval in 2025 [6]. - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, highlighting its competitive edge in the HIV treatment market [6]. Financial Data and Profit Forecast - Total revenue is projected to grow from 418 million yuan in 2024 to 1.263 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 26.7% [5]. - The net profit is expected to turn positive in 2025, reaching 7 million yuan, and further increasing to 166 million yuan by 2027, reflecting a significant growth trajectory [5]. - The gross margin is forecasted to improve from 54.9% in 2024 to 75.2% in 2027, indicating enhanced operational efficiency [5]. - The return on equity (ROE) is anticipated to rise from -14.4% in 2024 to 13.4% in 2027, suggesting a recovery in profitability [5].

Investment Rating - The industry investment rating is "Overweight," indicating a positive outlook for the IDC/Intelligent Computing Center sector [2]. Core Insights - The report highlights a consensus among AI industry leaders that domestic technology companies are transitioning from followers to leaders in global AI technology [2]. - Significant breakthroughs are expected in 2026 across multiple dimensions, including computing power, models, and applications, with a notable improvement in the usability of domestic computing power [2]. - The IDC sector is anticipated to undergo major changes in 2026, driven by the demand from cloud vendors and the need for efficient computing resources [2]. - The report emphasizes the scarcity of effective supply in the market, with government policies shifting focus from broad construction to orderly guidance and efficient resource allocation [2]. - Key companies identified for investment include leading IDC firms and those in the supply chain for power distribution and temperature control [2]. Summary by Sections Demand Side - High demand from cloud vendors is expected, with a significant number of IDC orders anticipated to be deployed by mid-2026 [2]. - The necessity for cloud vendors to secure quality assets for sustainable computing power supply is highlighted [2]. Supply Side - The report notes a strong scarcity of "effective supply," with government initiatives aimed at optimizing the layout of intelligent computing resources [2]. - The need for supporting equipment such as UPS/HVDC and liquid cooling systems is emphasized due to the redundancy requirements in power supply [2]. Key Companies - Core players in the IDC sector include Runze Technology, Dongyangguang, and Baoxin Software, among others [3]. - Companies with flexible demand and strong client ties, such as Dawi Technology and Aofei Data, are also highlighted as potential investment opportunities [2].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - The company plans to raise up to 185 million yuan through a simplified procedure for issuing A-shares, with funds allocated for acquiring a 22.2324% stake in Nanda Pharmaceutical and for supplementing working capital [6] - The acquisition will increase the company's direct stake in Nanda Pharmaceutical to 73.358%, which is expected to enhance the company's performance as Nanda reported a net profit of 55.81 million yuan from January to October 2025 [6] - The company is advancing its human-derived protein product pipeline, including new drugs AD010, AD108, and ADB116, with AD108 receiving clinical approval in 2025 for treating acute ischemic stroke [6] - The company showcased its third-generation integrase product ACC017 at the J.P. Morgan conference, indicating its commitment to becoming a leading brand in HIV innovation while expanding into international markets [6] Financial Summary - Projected total revenue for 2025 is 806 million yuan, with a year-on-year growth rate of 92.8% [5] - Expected net profit for 2025 is 7 million yuan, with a significant increase projected to 89 million yuan in 2026 and 166 million yuan in 2027 [5] - The gross margin is expected to improve from 63.2% in 2025 to 75.2% in 2027 [5]

Core Insights - The report highlights that Xinhecheng (002001) is positioned to become a global leader in the fine chemical industry by leveraging high-barrier core intermediates and focusing on domestic substitution [2][12] - The nutritional products segment is expected to recover, with methionine likely to see both volume and price increases as the impact of BASF's incident fades [12] - The flavor and fragrance segment is experiencing steady growth, with the company leading in domestic scale and continuously expanding its product offerings [12] - The new materials segment demonstrates synergy between industry and technology, with the company planning to enhance its production capacity for key intermediates like adiponitrile [12] Nutritional Products Segment - The nutritional products segment is at a turning point, with methionine demand expected to grow at 6% globally, supported by a strong cost curve and reduced overseas competition due to environmental pressures [12] - The company has a significant cost advantage by mastering core intermediates and integrating the vitamin A and E supply chain [12] - The anticipated completion of projects for 70,000 tons of solid methionine and 180,000 tons of liquid methionine in 2025 is expected to lead to volume and price increases in 2026 [12] Flavor and Fragrance Segment - The global flavor and fragrance market is dominated by a few players, with high barriers to entry, and the company is well-positioned to benefit from this concentration [12] - The segment is expected to grow as downstream manufacturers are less sensitive to price changes and seek comprehensive service offerings [12] New Materials Segment - The new materials segment is characterized by high-barrier processes and significant domestic substitution potential, with the company being the second-largest producer of PPS globally [12] - The company is planning a nylon integration project in Tianjin, with an initial capacity of 100,000 tons per year for adiponitrile and hexamethylenediamine [12] Financial Projections - Revenue projections for the company are estimated at 23.183 billion, 23.426 billion, and 24.478 billion yuan for 2025, 2026, and 2027 respectively, with net profit forecasts of 6.733 billion, 7.202 billion, and 8.058 billion yuan [12] - The expected EPS for the same years is 2.19, 2.34, and 2.62 yuan per share, indicating a compound annual growth rate (CAGR) of 11% for net profit [12] - The company's PE ratio for 2026 is projected to be around 11 times, which is below the average PE of comparable companies at 15 times [12]

Investment Rating - The report rates the AI healthcare industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [2][19]. Core Insights - The launch of OpenAI's ChatGPT Health on January 8, 2026, marks a significant advancement in AI healthcare, integrating user health data for personalized health analysis and recommendations. The user base of Ant Group's AI tool, Antifufu, has also seen substantial growth, surpassing 30 million monthly active users [2][5]. - The report highlights the rapid penetration of AI health management in the consumer market, driven by advancements in technology and user engagement [2][5]. - Key areas of progress include AI consultations, brain-computer interfaces, and AI-driven drug development, with notable advancements from companies like Neuralink and Retro Biosciences [10][13][14]. Summary by Sections AI Health Management - OpenAI's ChatGPT Health integrates personal health data, offering features such as test report interpretation, health management, and personalized diet and fitness recommendations. The tool emphasizes user privacy and data security [4][7]. - Antifufu has integrated over 100 AI functions, connecting users with 300,000 real doctors and over 500 AI avatars, achieving a doubling in user engagement metrics within a month [8][9]. AI Consultation and Drug Development - The report notes significant improvements in AI consultation tools, with various companies like Weining Health and JD Health being highlighted for their contributions to AI health management [15]. - In drug development, OpenAI's collaboration with Retro Biosciences has led to the clinical advancement of a small molecule drug targeting aging, showcasing the potential of AI in pharmaceutical innovation [13][14]. Market Performance and Company Valuations - The report provides a valuation table for key companies in the AI healthcare sector, indicating projected net profits and market capitalizations for 2024 to 2027. For instance, Weining Health is projected to have a market cap of 31 billion with a net profit of 3.5 billion by 2026 [14].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the near term [7][19]. Core Insights - The company has demonstrated strong revenue growth, with a projected increase in operating income from 84.23 billion RMB in FY2023 to 130.8 billion RMB by FY2027, reflecting a compound annual growth rate (CAGR) of approximately 8% [7][19]. - The net profit attributable to shareholders is expected to grow from 9.6 billion RMB in FY2023 to 15.1 billion RMB in FY2027, with a steady growth trajectory [7][19]. - The company has successfully expanded its "super premium" store concept, with 126 stores opened by the end of 2025, exceeding expectations and contributing to its revenue growth [7][19]. - The company has maintained a stable discount rate of 7-7.1, indicating effective inventory management and pricing strategy [7][19]. - The introduction of new product lines and strategic marketing partnerships has enhanced brand visibility and sales performance, particularly in the running and basketball segments [7][19]. Financial Data and Profit Forecast - Revenue projections for FY2023 to FY2027 are as follows: 84.23 billion RMB, 100.7 billion RMB, 111.8 billion RMB, 121.4 billion RMB, and 130.8 billion RMB, respectively, with corresponding growth rates of 21%, 20%, 11%, 9%, and 8% [7][19]. - Net profit forecasts for the same period are 9.6 billion RMB, 11.5 billion RMB, 12.6 billion RMB, 13.9 billion RMB, and 15.1 billion RMB, with growth rates of 29%, 20%, 10%, 10%, and 9% [7][19]. - The company's gross margin is projected to improve slightly from 41.1% in FY2023 to 41.9% in FY2027, indicating efficient cost management [7][19].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has demonstrated strong growth momentum with double-digit revenue growth, particularly in the fourth quarter of 2025, where both adult and children's apparel retail sales increased by approximately 10% year-on-year [7] - The expansion of super stores has exceeded expectations, with a total of 126 super stores opened by the end of 2025, including 21 children's clothing stores, contributing significantly to offline growth [7] - The company maintains a healthy inventory level with a stable discount rate, indicating robust operational performance [7] - Product innovation and enhanced marketing strategies are driving brand strength, with new product launches in running and basketball categories [7] - The company is also expanding its outdoor brand "One Way," which is expected to capitalize on the growing outdoor trend [7] - The financial forecasts indicate a steady increase in revenue and net profit, with projected net profits of 12.6 billion, 13.9 billion, and 15.1 billion RMB for FY2025, FY2026, and FY2027 respectively [6][18] Financial Data and Profit Forecast - Revenue projections are as follows: - FY2023: 84.23 billion RMB - FY2024: 100.7 billion RMB - FY2025E: 111.8 billion RMB - FY2026E: 121.4 billion RMB - FY2027E: 130.8 billion RMB - Net profit projections are as follows: - FY2023: 9.6 billion RMB - FY2024: 11.5 billion RMB - FY2025E: 12.6 billion RMB - FY2026E: 13.9 billion RMB - FY2027E: 15.1 billion RMB - The company’s gross margin is expected to improve slightly from 41.1% in FY2023 to 41.9% in FY2027 [6][18]